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Abstract: Background: Hederacoside C from ivy leaf dry extracts (HH) and berberine from Coptidis
rhizome dry extracts (CR) can be combined (HHCR) as a herbal product. Previous studies have
demonstrated that HHCR has antitussive and expectorant effects in animal models of respiratory
disease. However, the therapeutic effects of HHCR on respiratory diseases in humans have not been
well-studied. Therefore, we aimed to clarify the effectiveness of HHCR in patients with chronic
bronchitis and bronchiectasis. Methods: This was a multicenter (10 university teaching hospitals),
open-label, prospective, single-arm, observational study. Consecutive patients with chronic bronchitis
and bronchiectasis were included. Patients were orally treated with HHCR daily for 12 weeks.
St. George’s Respiratory Questionnaire (SGRQ) scores and bronchitis severity scores (BSS) were
measured at baseline and at the end of the 12-week study. Results: In total, 376 patients were enrolled,
of which 304 were finally included in the study, including 236 males and 68 females with a median
age of 69 years (range: 37–88 years). After 12 weeks of HHCR treatment, there was a significant
improvement in SGRQ score (baseline, 32.52 ± 16.93 vs. end of study, 29.08 ± 15.16; p < 0.0001)
and a significant reduction in BSS (baseline, 7.16 ± 2.63 vs. end of study, 4.72 ± 2.45; p < 0.0001).
During the study, 14 patients concomitantly used an inhaled corticosteroid and 83 patients used an
inhaled bronchodilator. HHCR also had significant positive effects on these patients in terms of SGRQ
score and BSS. No serious adverse drug reactions occurred during HHCR treatment. Conclusions:
treatment with HHCR improved the SGRQ score and BSS in patients with chronic bronchitis and
bronchiectasis. HHCR may be a new therapeutic option for chronic bronchitis and bronchiectasis.
Large-scale, randomized, double-blind, placebo-controlled clinical trials are warranted.
Keywords: chronic bronchitis; bronchiectasis; hederacoside C; berberine; mucolytic agent
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1. Introduction
Bronchiectasis is a chronic respiratory disorder associated with poor quality of life
(QOL) and frequent exacerbations. There are some international guidelines on treatment
of bronchiectasis, including The European Respiratory Society (ERS) and British Thoracic
Society (BTS) guidelines. Chronic bronchitis may degrade lung function and increase the
rate of exacerbation, resulting in clinical consequences such as aggravate health-related
QOL and increase the possibility of mortality [1]. The severity of symptoms in patients
with bronchiectasis and chronic bronchitis is related to chronic mucus hypersecretion
and mucus plugging. Impairment of mucociliary transport is induced by the impact of
structural changes in airway cellular architecture, airway dehydration, and excess mucus
volume and viscosity. More than 70% of bronchiectasis patients expectorate highly variable
volumes of sputum daily. Treatment aims to prevent mucus stasis and plugging, airflow
obstruction, and progressive lung damage [2].
Large quantities of Coptidis rhizome (CR) are consumed in Asian countries, including
China, Japan, Malaysia, Singapore, and India, but very little is used in European coun-
tries [3]. The therapeutic characteristics of berberine, the main ingredient of CR, are the
suppression of inflammation by inhibiting the lipopolysaccharide (LPS)-stimulated pro-
inflammatory cytokines, such as interleukin-6 and LPS-mediated nuclear factor (NF)-kB
activation [4]. Kim et al. [5]. reported that berberine suppresses the expression of the
MUC5AC gene, which is primarily involved in mucin production in chronic inflammatory
airway diseases, and some studies have shown that berberine exhibits bronchodilatory and
antimicrobial activities [6]. Hederacoside C (HH), the aglycone part of ivy leaf extract, has
long been used to treat respiratory diseases by blocking inflammatory mediators such as
bradykinin to exert anti-inflammatory effects [7].
HHCR is a herbal product consisting of HH from ivy leaf dry extracts and berberine
from CR dry extracts. HHCR is approved in the Republic of Korea for the relief of cough
and sputum formation due to acute respiratory infection and inflammation. The research
on CR and HH has mostly focused on molecular mechanisms using animal studies [5,6,8,9].
Although the mechanism of action of HHCR is known, details of its therapeutic effects
on chronic bronchitis and bronchiectasis are not well-known. This study investigated the
effectiveness of oral HHCR in patients with chronic bronchitis and bronchiectasis.
2. Materials and Methods
2.1. Study Design
This 12-week, open-label, multicenter, prospective, single-arm, observational study
was conducted at 10 university teaching hospitals in the Republic of Korea. The first patient
was enrolled on 25 September 2017, and the last patient was examined on 28 June 2018.
The study protocol was designed by the investigator steering committee and presented
to all study locations thereafter. All investigators were trained before the trial to ensure
reliable data quality, with special emphasis on understanding the protocol. The study
was conducted in accordance with the Declaration of Helsinki, and Good Clinical Practice
Guidelines. The protocol was approved by the institutional review board at each study
center, and all patients gave written informed consent before participating in any study
procedures.
Patients were seen at the initial visit, at week 4 after enrollment, and at week 12 of the
study; any unscheduled visits were recorded. Patients were treated orally with fixed dose
15 mg of HHCR three times daily (Synatura®; Ahn-Gook Pharmaceutical Co., LTD., Seoul,
Korea) for 12 weeks. At every visit, adherence to the study regimen was assessed. The
study flowchart is shown in Figure 1. No follow-up study was planned.
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Figure 1. Study design. 
Salbutamol, a short-acting β2-agonist, was administered as needed to relieve symp-
toms. Maintenance treatment for chronic obstructive pulmonary disease (COPD) that 
started prior to the study, including the use of short-acting bronchodilators, long-acting 
bronchodilators such as long-acting β2-agonists and long-acting muscarinic antagonists, 
inhaled corticosteroids (ICS), and methylxanthines such as theophylline and doxofylline, 
was permitted to continue during the study period, whereas the use of mucoactive drugs, 
antitussives, antibiotics, and systemic corticosteroids was prohibited to avoid any poten-
tial confounding effects on clinical endpoints. 
2.2. Patient Participation 
Patients aged ≥35 years, regardless of whether they were smokers or non-smokers, 
were eligible if they had been diagnosed with chronic bronchitis based on the Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD) guidelines [10] or bronchiectasis. 
The definition of chronic bronchitis is chronic cough and sputum production for at least 3 
months per year for 2 consecutive years. Bronchiectasis was diagnosed using a computed 
tomography scan and previously recorded diagnostic criteria findings. 
Exclusion criteria were: acute exacerbation of chronic bronchitis, continuous treat-
ment with systemic corticosteroids, active infection due to Mycobacterium tuberculosis (ex-
cept for patients with small, old tuberculous lesions), pneumonia, history of active peptic 
ulcer disease or intestinal malabsorption, congestive heart failure categorized as class 2 or 
higher according to the New York Heart Association, severe neurological disease, severely 
impaired hepatic or renal function, immunocompromised status, suspected or known hy-
persensitivity to the study product or any of its excipients, rare hereditary problem of 
fructose intolerance, pregnancy or active lactation status, poor reliability (e.g., history of 
alcohol or drug abuse, mental disorder), and poor compliance. 
2.3. Efficacy Outcomes and General Measures 
The primary endpoint was the change in St. George’s Respiratory Questionnaire 
(SGRQ) score between the baseline and week 12. The SGRQ is disease-specific instrument 
designed to assess of quality of life. It is consists of 50 items divided into three compo-
nents: symptom component, activity component, and impact component. Each score of 
components and total score are calculated. The SGRQ is displayed with a score ranging 
from 0 to 100, where 0 indicates the best quality of life related to health, and the higher 
score means a poorer quality of life. 
The secondary endpoint was the change in Bronchitis Severity Score (BSS) between 
the baseline and week 12. The BSS was developed to measure an appropriate outcome of 
bronchitis [11]. The scale comprises the five most important features of bronchitis, i.e., 
coughing, sputum production (expectoration), rales/rhonchi (auscultation), chest pain 
while coughing, and dyspnea. This instrument combines objective and subjective items, 
because the assessment is based on the investigator’s clinical evaluation in conjunction 
with subjective feedback from the patient. Each constituent of the BSS is assessed by the 
investigator using a five-point verbal rating scale ranging from 0 to 4 (0, absent; 1, mild; 
Figure 1. Study design.
Salbutamol, a short-acting β2-agonist, was administered as needed to relieve symp-
toms. Maintenance treatment for chronic obstructive pulmonary disease (COPD) that
started prior to the study, including the use of short-acting bronchodilators, long-acting
bronchodilators such as long-acting β2-agonists and long-acting muscarinic antagonists,
inhaled corticosteroids (ICS), and methylxanthines such as theophylline and doxofylline,
was permitted to continue during the study period, whereas the use of mucoactive drugs,
antitussives, antibiotics, and systemic corticosteroids was prohibited to avoid any potential
confounding effects on clinical endpoints.
2.2. Patient Participation
Patients aged ≥35 years, regardless of whether they were smokers or non-smokers,
were eligible if they had been diagnosed with chronic bronchitis based on the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [10] or bronchiectasis.
The definition of chronic bronchitis is chronic cough and sputum production for at least
3 months per year for 2 consecutive years. Bronchiectasis was diagnosed using a computed
tomography scan and previously recorded diagnostic criteria findings.
Exclusion criteria were: acute exacerbation of chronic bronchitis, continuous treatment
with systemic corticosteroids, active infection due to Mycobacterium tuberculosis (except
for patients with small, ld tuberculous lesions), pneumonia, history of active peptic
ulcer diseas or intestinal malabsorption, congestive heart failure categorized as class 2 or
higher according to the New York Heart Association, severe neurological dise e, severely
impaired hepatic or renal function, immunocompromis d status, suspected or known
hype sensitivity to the study product or any of its excipients, rare hereditary pr blem of
fructo e in oleranc , pregnancy or active lactation status, poor reliability (e.g., history of
alcohol or drug abuse, mental disorder), and poor compliance.
2.3. Efficacy Outcomes and General Measures
The primary ndpoint w s the change in St. George’s Respiratory Questionnaire
(SGRQ) score between the baseline and week 12. The SGRQ is disease-specific instrument
designed to assess of quality of life. It is consists of 50 items divided into three components:
symptom component, activity component, and impact component. Each score of compo-
nents and total score are calculated. The SGRQ is displayed with a score ranging from 0 to
100, where 0 indicates the best quality of life related to health, and the higher score means
a poorer quality of life.
The secondary endpoint was the change in Bronchitis Severity Score (BSS) between
the baseline and week 12. The BSS was developed to measure an appropriate outcome
of bronchitis [11]. The scale comprises the five most important features of bronchitis, i.e.,
coughing, sputum production (expectoration), rales/rhonchi (auscultation), chest pain
while coughing, and dyspnea. This instrument combines objective and subjective items,
because the assessment is based on the investigator’s clinical evaluation in conjunction
with subjective feedback from the patient. Each constituent of the BSS is assessed by the
investigator using a five-point verbal rating scale ranging from 0 to 4 (0, absent; 1, mild; 2,
moderate; 3, severe; 4, very severe). The total score is the sum of the five ratings with a
maximum of 20 points. Since its introduction in 1996, the BSS has been successfully used in
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many clinical studies as a main outcome measure for patients suffering from bronchitis [12].
An additional efficacy endpoint was the association between variation in SGRQ scores and
variation in BSS.
Patients were first seen at a screening visit during which inclusion/exclusion criteria,
medical and medication history, and the status of exacerbations were checked, and the
results of a physical examination, chest radiograph, electrocardiography (ECG), laboratory
tests, and pregnancy test as well as the SGRQ score and BSS were recorded. Patients who
met the inclusion criteria were asked to sign the informed consent form. After the start of
the study, patients returned to the investigation center at weeks 4 and 12. At each visit, the
following information was recorded: physical examination results, pregnancy test results,
concomitant medications (including ICS, and short- and long-acting bronchodilators),
occurrence of spontaneous adverse events (AEs), and level of compliance. At week 12, the
SGRQ and BSS were assessed again.
Safety assessments included the recording of AEs, laboratory tests, blood pressure
measurements, and 12-lead ECG. All adverse events or concurrent illnesses during the
study were documented in the clinical record form. Major adverse cardiovascular events
(MACE; a composite of total cardiovascular death, non-fatal myocardial infarction, and
non-fatal stroke) were evaluated and classified by an independent, blinded adjudication
committee. AEs were evaluated and presented descriptively. An AE was defined as any
untoward medical occurrence in a patient who was administered the study drug, regardless
of whether it was considered to be related to the study drug. An AE was considered serious
if it was either immediately life threatening or resulted in persistent or significant disability,
prolonged hospitalization, or death.
2.4. Statistical Analysis
All data are presented as medians or the means ± standard deviations (SDs) for
continuous variables and as numbers with percentages in parentheses for categorical
variables. The primary positive outcome in the study would be an improvement in the
SGRQ score and BSS after 12 weeks of HHCR treatment. Changes from baseline to the
endpoints were analyzed using the paired t-test. All statistical analyses were performed
using SAS for Windows software (9.4; SAS Institute Inc., Cary, NC, USA). A value of
p < 0.05 was considered to denote significance.
3. Results
3.1. Study Population and Baseline Characteristics
Of 377 eligible patients with chronic bronchitis or bronchiectasis who were recruited,
one patient was excluded during the screening period due to withdrawn consent. Of the
72 (19.2%) patients who discontinued treatment, 27 (7.2%) were lost to follow-up, 15 (4%)
had protocol violations, 14 (3.7%) withdrew consent, 5 (1.3%) had AEs, 5 (1.3%) were
non-compliant, and 6 (1.6%) discontinued for other reasons.
Patient demographics and baseline characteristics are summarized in Table 1. The
median age of the patients was 69 years (range, 37–88 years) at inclusion, and male patients
accounted for 77.6% (236 patients) of the patient group. The mean body mass index (BMI)
of the whole group was 22.83 ± 3.33. Pharmacologic treatments for chronic bronchitis
and bronchiectasis, taken occasionally or routinely during the last three months prior to
enrolment, are listed in Table 2.
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Table 1. Baseline characteristics of the study population.





Mean ± SD 67.88 ± 8.94
Median 69.00
Min, Max 37.00, 88.00
Height (cm)
Mean ± SD 163.27 ± 7.70
Median 164.00
Weight (kg)
Mean ± SD 60.93 ± 10.31
Median 60.35
Min, Max 37.00, 90.00
BMI (kg/m2)
Mean ± SD 22.83 ± 3.33
Median 22.75
Min, Max 13.68, 31.60
n (%), number of patients (percentage of patients); SD, standard deviation; Min, minimum; Max, maximum; BMI,
body mass index.
Table 2. Pharmacologic treatment for chronic bronchitis and bronchiectasis at entry.
Drug Name Total (n = 304)
Use of any concomitant drug (n (%))
ICS alone












Aclidinium bromide 9 (2.96)
Umeclidinium bromide 1 (0.33)
Tiotropium bromide 33 (10.86)
LABA-LAMA
Olodaterol/Tiotropium bromide 27 (8.88)
Indacaterol/Glycopyrronium bromide 23 (7.57)
















n (%), number of patients (percentage of patients); ICS, inhaled corticosteroid; LABA, long-acting beta-agonist;
LAMA, long-acting muscarinic antagonist.
3.2. Primary Endpoint
The median total SGRQ score was 29.96 (range, 4.07–96.16) and the mean was 32.52 ± 16.93
(SD) at baseline. At week 12, a median score of 25.64 (range, 3.86–89.35) and a mean score
of 29.08 ± 15.16 were reported. Patients treated with HHCR exhibited a statistically
significant and clinically relevant improvement from baseline in terms of SGRQ total score,
with median reduction in score of −2.37 and a mean reduction of −3.44 ± 10.97 (p < 0.0001)
after 12 weeks of treatment (Figure 2). Of the SGRQ domains, statistically significant and
clinically relevant improvements were seen in the symptoms (median score reduction,
−2.94; mean score reduction, −5.01 ± 12.21; p <0.0001) and impact domains (median score
reduction, −2.28; mean score reduction, −4.37 ± 13.33; p < 0.0001) after 12 weeks. The
activity domain score also improved (mean score reduction, −0.97 ± 14.76; p = 0.0971), but
the difference was not statistically significant (Figure 2).
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Figure 2. Change from baseline in St. George’s Respiratory Questionnaire (SGRQ) total scores,
activity domain, impact domain, and symptom dom in. p-value < 0.0001 (Cf. Activity p-value:
0.0971) Wilcoxon’s signed-rank test. *: Statistically significant difference.
3.3. Secondary Endpoint
The total median and mean BSS at baseline were 7.0 (range, 2.0–15.0) and 7.16 ± 2.63,
respectively, and the total median and mean scores at week 12 were 4.50 (range, 0.0–13.0)
and 4.72 ± 2.45, respectively. Patients treated with HHCR exhibited a statistically significant
and clinically relevant improvement from baseline in terms of total BSS, with a median
score reduction of −2.0 and a mean score reduction of −2.45 ± 2.36 (p < 0.0001) after
12 weeks of treatment (Figure 3). Of the BSS components, statistically significant and
clinically relevant improvements were seen after 12 weeks in terms of scores related to
coughing (median score reduction, −1.0; mean score reduction, −0.53 ± 0.77; p < 0.0001),
sputum production (median score reduction, −1.0; mean score reduction, −0.77 ± 0.88;
p < 0.0001), auscultation (median score reduction, 0.0; mean score reduction, −0.49 ± 0.76;
p < 0.0001), chest pain while coughing (median score reduction, 0.0; mean score reduction,
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−0.20 ± 0.56; p < 0.0001), and dyspnea (median score reduction, 0.0; mean score reduction,
−0.46 ± 0.80; p < 0.0001) (Figure 3). The correlation coefficient for the relationship between
the SGRQ score and BSS was 0.3766 (p < 0.0001). A scatter plot of the variation in BSSs vs.
variation in SGRQ scores is shown in Figure 4.
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3.4. Changes in SGRQ Score and BSS in Patients Concomitantly Treated with a Bronchodilator
In total, 83 patients were treated concomitantly with a bronchodil tor during the
12-week study period. For these patients, the total median SGRQ score was 35.81 (range,
5.57–96 16) and the me n score was 37.66 ± 8.54 at baseline. At w ek 12, a median score
of 29.86 (range, 7.99–89.35) and a mean score of 34.51 ± 17.74 were rep rt d. Patients
treated with HHCR exhibited a statistically significant and clinically relevant improvement
from bas line in terms of SGRQ total score, with a median score duction of −1.71 and a
mean score reduction of −3.15 ± 13.31 (p = 0.0115) after 12 weeks of tr atment. Statistically
significant and clinically relevant improvements after 12 weeks were seen in the symptoms
(mean score reduction, −5.19 ± 15.83; p = 0.0049) and impact (mean score reduction,
−3.84 ± 15.21; p = 0.014) domain scores. The activity domain score improved (mean score
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reduction, −0.80 ± 17.38; p = 0.4788), but the improvement was not statistically significant
(Figure 5).
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Figure 5. Change of SGRQ and BSS in patients who had concomitant treatment with bronchodilator p-value < 0.0001 (Cf.
‘’Chest pain” p-value: 0.0514) Wilcoxon’s signed-rank test. *: Statistically significant difference.
The median and mean total BSS at baseline were 7.0 (range, 2.0–13.0) and 6.88 ± 2.75,
respectively, and the median and mean total scores at week 12 were 4.0 (range, 0.0–12.0)
and 4.55 ± 2.35, respectively. The change in total BSS from baseline to week 12 reflected a
statistically significant and clinically relevant improvement, with a median score reduction
of −2.0 and a mean score reduction of −2.33 ± 2.66 (p < 0.0001). Of the BSS components,
statistically significant and clinically relevant improvements were seen after 12 weeks in
terms of scores related to coughing (median score reduction, −1.0; mean score reduction,
−0.48 ± 0.94; p < 0.0001), sputum production (median score reduction, −1.0; mean score
reduction, −0.66 ± 0.91; p < 0.0001), auscultation (median score reduction, 0.0; mean score
reduction, −0.37 ± 0.79; p < 0.0001), chest pain while coughing (median score reduction,
0.0; mean score reduction, −0.12 ± 0.50; p = 0.0514), and dyspnea (median score reduction,
−1.0; mean score reduction, −0.69 ± 0.85; p < 0.0001) (Figure 5).
3.5. Safety and Tolerability
Based on pooled analysis of safety data, 30 AEs were reported by 28 patients (9.21%)
from the treatment population during the 12-week study. Most AEs were mild in severity
and generally well-tolerat d. The most frequent AEs were respiratory symptoms, including
coughing, dyspnea, rhinorrhea, and sore throat, followed by gastrointestinal symptoms
such as nausea, gastric irritation, and heartburn. Neurologic sympto s such as insom-
nia and myalgia were also reported. Of the 30 AEs, only four were determined by the
investigators to be related to the study drug. A summary of reported AEs is shown in
Table 3.
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Table 3. Summary of reported adverse events (AEs).
Total (n = 304)















AE, adverse event; n, number; SAE, serious adverse event; ADR, adverse drug reaction; SADR, severe adverse
drug reaction; MACE, major adverse cardiovascular events.
In all, three patients (0.99%) reported three serious AEs, including two cases of dyspnea
and one increase in prostate specific antigen. However, two of the serious AEs were
determined by the investigators to be unrelated to the study drug. Only one patient (0.3%)
discontinued HHCR treatment because of a serious AE (dyspnea). All the AEs improved
spontaneously during treatment with HHRC; therefore, these AEs were not causally related
to HHCR treatment. During the 12-week observation period, no MACE or fatal outcomes
were reported. No abnormal findings were observed in chest radiographs, ECG outputs,
or laboratory tests, including tests for full blood count, blood chemistry, and urinalysis
during the study period.
4. Discussion
Bronchiectasis is a chronic respiratory disease, radiologically characterized by abnor-
mal and permanent expansion of the bronchi, and clinical syndromes such as sputum
production, cough, and bronchial infection [13]. Sputum production, coughing, and
breathlessness are the most frequent symptoms [14]. Treatment is primarily based on the
principles of preventing exacerbations, suppressing acute and chronic bronchial infection,
reducing symptoms, improving mucociliary clearance and QOL, and preventing disease
progression [14]. Exacerbation of bronchiectasis is the main objective for treatment since it
is related to airway increase and systemic inflammation [15] as well as progressive lung
damage [16,17]. In addition, more severe and frequent exacerbations are associated with
worse QOL, daily symptoms [18], lung function decline [19], mortality, and higher health-
care costs. Despite current treatment approaches, about half of patients with bronchiectasis
suffer more than two exacerbations per year, and about 33% patients require at least one
hospitalization per year [20].
Chronic bronchitis result from goblet cells producing and secreting excessive mucus.
By luminal obstruction of small airways, epithelial remodeling, and alteration of airway sur-
face tension, it contributes to aggravating airflow obstruction and finally make the airway
vulnerable to collapse. Despite the clinical sequelae, there is only limited information on
the pathophysiology of chronic bronchitis and goblet cell hyperproliferation of COPD, and
there are insufficient alternatives for treatment [1]. Impairment of mucociliary clearance is
a representative pathologic feature of bronchiectasis and chronic bronchitis, and it results
in various respiratory symptoms, including coughing and sputum production [2].
There has been a persistent effort to use traditional natural products as respiratory
medications to alleviate coughing and sputum production for thousands of years. HHCR is
a natural medicine reported to suppress pulmonary inflammation, and it has been shown
to have expectorant and antitussive effects in animals [9]. QOL impairment in chronic
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bronchitis and bronchiectasis is equivalent in terms of SGRQ scores to severe COPD,
idiopathic pulmonary fibrosis, and other disabling respiratory diseases [21,22]. In this
study, we focused on the symptomatic improvement of patients with chronic bronchitis
and bronchiectasis after treatment with HHCR by evaluating the effects of HHCR on SGRQ
score and BSS.
The results of our study indicate that HHCR is able to reduce the respiratory symptoms
of patients with chronic bronchitis and bronchiectasis. Treatment with HHCR improved
both SGRQ score and BSS. Moreover, subgroup analysis of the changes in SGRQ score
and BSS among patients concomitantly treated with a bronchodilator showed that the
SGRQ score and BSS improved in this patient group compared with the group with no
concomitant bronchodilator treatment. Previous study has suggested that HHCR is a
potential useful therapeutic option for respiratory diseases [9]. However, there have
been few studies on the effects of HHCR in humans. This is the first study to elucidate
the possible benefits of HHCR for the treatment of patients with chronic bronchitis and
bronchiectasis.
HH is a triterpene saponin and an active ingredient derived from ivy leaf extracts.
It exhibits biological properties such as expectorant and bronchospasmolytic effects, and
hence has been therapeutically applied for the treatment of chronic inflammatory bronchial
conditions and productive coughs [7,23,24]. CR comprises various alkaloid constituents,
such as berberine, coptisine, palmatine, and epiberberine; among them, berberine is the
most potent. Berberine have bronchodilating and antimicrobial action and may suppress
the mucin in sputum [6]. These actions are accomplished by a mechanism that inhibits the
expression of IL-1β-induced MUC5AC gene in human airway epithelial cells through ERK
and p38MAPK. This indicates that berberine has antitussive and expectorant effects.
Chronic bronchitis and bronchiectasis with acute exacerbations are difficult to treat,
resulting in high morbidity and mortality. Unfortunately, no foundational treatment agent
has been identified. Some mucolytics and expectorants such as N-acetylcysteine, erdostein,
and ambroxol are used for reducing mucus secretion and promoting mucus clearance,
but there have been concerns about their effectiveness, limitations, and side effects [25].
Our study suggests that a course of oral HHCR might have symptomatic and clinical
advantages in patients with chronic bronchitis and bronchiectasis.
Nevertheless, the study has some limitations. First, this was an open-label, single-arm,
observational trial, and treatment with a bronchodilator and ICS was permitted. This
open design might have biased the results, and the use of concomitant treatment is a
possible confounding factor. However, there were no significant differences in the use of
bronchodilator treatments from baseline to week 12 in all enrolled patients, and HHCR
treatment was uniformly administrated to all patients in the study. Additionally, regarding
the bronchodilator, out study’s bronchodilator uses were not specialized as short-acting
or long-acting. Therefore, the difference in effect between each type of bronchodilator is
limited. Despite this limitation, this pilot clinical trial is the first one performed in patients.
Further large-scale placebo-controlled studies are warranted. Second, objective parameters
of airway inflammation such as cytokines, chemokines, and sputum inflammatory cells
were not estimated. However, the focus of this study was to determine an individual’s
health-related QOL change using validated and widely accepted instruments such as the
SGRQ and BSS. Third, our study’s design investigated 12 weeks only, so further further
safety evaluations for extended periods and patient outcomes needed (e.g., exacerbation
rate after treatment completed). However, clinical improvements and no serious AEs
after 12 weeks of treatment could be considered reasonable treatment goals for chronic
bronchitis and bronchiectasis. Finally, we did not evaluate correlations between HHCR and
lung function/clinical parameters. Further large-scale clinical trials are needed to elucidate
these correlations.
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5. Conclusions
Despite some limitations, the results of this observational, real-world trial revealed that
patients with chronic bronchitis and bronchiectasis experienced considerable and clinically
relevant improvements in health-related QOL, with improvements in the total BSS score
and all five domain scores as well as the SGRQ total score and all three domain scores after
treatment with HHCR. The changes in SGRQ score and BSS among patients concomitantly
treated with a bronchodilator showed that the SGRQ score and BSS improved in this
patient group compared with the group with no concomitant bronchodilator treatment.
The potential attenuation of symptom progression associated with chronic bronchitis and
bronchiectasis reported in this study suggests that HHCR may be a reasonable therapeutic
agent for further prospective placebo-controlled trials.
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